Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Formylpeptide receptor 1 contributes to epidermal barrier dysfunction-induced skin inflammation through NOD-like receptor C4-dependent keratinocyte activation.
Shao S, Sun Z, Chu M, Chen J, Cao T, Swindell WR, Bai Y, Li Q, Ma J, Zhu Z, Schuler A, Helfrich Y, Billi AC, Li Z, Hao J, Xiao C, Dang E, Gudjonsson JE, Wang G. Shao S, et al. Among authors: helfrich y. Br J Dermatol. 2024 Mar 15;190(4):536-548. doi: 10.1093/bjd/ljad455. Br J Dermatol. 2024. PMID: 37979162
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.
Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Furie RA, et al. N Engl J Med. 2022 Sep 8;387(10):894-904. doi: 10.1056/NEJMoa2118025. N Engl J Med. 2022. PMID: 36069871 Clinical Trial.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Clark G, Carroll H, Naik H, Gaudreault F, Meyers A, Barbey C, Musselli C, Franchimont N; LILAC Trial Investigators. Werth VP, et al. N Engl J Med. 2022 Jul 28;387(4):321-331. doi: 10.1056/NEJMoa2118024. N Engl J Med. 2022. PMID: 35939578 Clinical Trial.
Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, Chen C, Riblett M, Johnston A, Gudjonsson JE, Helfrich Y, Kang S, Fisher GJ, Voorhees JJ. Wang F, et al. Among authors: helfrich y. Br J Dermatol. 2012 Jul;167(1):92-102. doi: 10.1111/j.1365-2133.2012.10961.x. Br J Dermatol. 2012. PMID: 22458549 Free article.
Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents.
Tsoi LC, Patrick MT, Shuai S, Sarkar MK, Chi S, Ruffino B, Billi AC, Xing X, Uppala R, Zang C, Fullmer J, He Z, Maverakis E, Mehta NN, Perez White BE, Getsios S, Helfrich Y, Voorhees JJ, Kahlenberg JM, Weidinger S, Gudjonsson JE. Tsoi LC, et al. Among authors: helfrich y. J Allergy Clin Immunol. 2022 Feb;149(2):640-649.e5. doi: 10.1016/j.jaci.2021.07.024. Epub 2021 Jul 31. J Allergy Clin Immunol. 2022. PMID: 34343561 Free PMC article.
Noninvasive Tape-Stripping with High-Resolution RNA Profiling Effectively Captures a Preinflammatory State in Nonlesional Psoriatic Skin.
Tsoi LC, Xing X, Xing E, Wasikowski R, Shao S, Zeng C, Plazyo O, Kirma J, Jiang Y, Billi AC, Sarkar MK, Turnier JL, Uppala R, Smith KM, Helfrich Y, Voorhees JJ, Maverakis E, Modlin RL, Kahlenberg JM, Scott VE, Gudjonsson JE. Tsoi LC, et al. Among authors: helfrich y. J Invest Dermatol. 2022 Jun;142(6):1587-1596.e2. doi: 10.1016/j.jid.2021.09.038. Epub 2021 Nov 19. J Invest Dermatol. 2022. PMID: 34808239 Free PMC article.
Overview of skin aging and photoaging.
Helfrich YR, Sachs DL, Voorhees JJ. Helfrich YR, et al. Dermatol Nurs. 2008 Jun;20(3):177-83; quiz 184. Dermatol Nurs. 2008. PMID: 18649702 Review.
50 results